Open AccessIneffective Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Monotherapy in Dyslipidemia with Low-Density Lipoprotein Cholesterol (LDL-C) Receptor Abnormalities: A Report of 2 Cases
Author(s) -
Anthony Matta,
Dorota Taraszkiewicz,
Vanina Bongard,
Jean Ferrières
Publication year - 2020
Publication title -
american journal of case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.247
H-Index - 18
ISSN - 1941-5923
DOI - 10.12659/ajcr.923722
Subject(s) - pcsk9 , alirocumab , medicine , evolocumab , kexin , ldl receptor , proprotein convertase , familial hypercholesterolemia , context (archaeology) , dyslipidemia , statin , subtilisin , pharmacology , ezetimibe , endocrinology , oncology , cholesterol , lipoprotein , biochemistry , disease , paleontology , apolipoprotein a1 , biology , enzyme , chemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom